KPV

KPV is a naturally occurring tripeptide (L-lysine–L-proline–L-valine) corresponding to the C-terminal fragment of alpha-melanocyte-stimulating hormone, α-MSH(11–13). It is the smallest sequence of the parent hormone that retains the hormone's anti-inflammatory activity, while carrying none of its pigmentary effects. Its short chain gives it unusual stability and the ability to cross cell membranes intact.

Mechanism

Unlike most peptides, KPV acts both at the cell surface and inside the cell. Research indicates it is transported into the cytoplasm, where it interferes with pro-inflammatory signalling by suppressing NF-κB nuclear translocation and downstream MAP kinase activity. The result is a reduction in the production of inflammatory cytokines such as TNF-α, IL-6 and IL-1β at their source, rather than a blockade of a single receptor.

What the research shows

• Marked reduction in inflammatory cytokine expression in epithelial and immune cell models
• Improved intestinal barrier integrity and reduced colonic inflammation in experimental colitis models
• Accelerated wound closure and reduced tissue oedema in dermal repair studies
• Antimicrobial activity against several bacterial and fungal strains in vitro
• Stable enough for oral, topical and parenteral administration in research settings — rare among peptides

KPV is studied as a broad, well-tolerated anti-inflammatory signal that works upstream of the inflammatory cascade, which is why it appears across gut, skin and joint research literature.